We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Assay Recommended for Heart Failure Diagnosis

By LabMedica International staff writers
Posted on 02 Apr 2018
Print article
Image: The cobas e 601 immunology analyzer (Photo courtesy of Roche Diagnostics).
Image: The cobas e 601 immunology analyzer (Photo courtesy of Roche Diagnostics).
The value of a biomarker to accurately diagnose or rule out acute heart failure in patients seen for shortness of breath at hospital emergency departments has been validated.

N-terminal pro-brain natriuretic peptide (NT-proBNP) and a related protein called (B-type natriuretic peptide (BNP) are both produced when the cardiac muscle is under stress.

A multi-institutional team led by those at the Massachusetts General Hospital (Boston, MA, USA) enrolled 1,461 adult patients who had come to hospital emergency departments (ED) with shortness of breath or other breathing difficulties. The study was conducted in 2015 and 2016 at 19 sites in the USA and Canada. Blood samples to be measured for NT-proBNP levels were taken upon study enrollment, and determination of the presence of acute heart failure. A cobas e 601 analyzer was used for all NT-proBNP measurements. Primary endpoints were positive predictive values of age-stratified cutoffs (450, 900, and 1,800 pg/mL) for diagnosis of acute heart failure (HF) and negative predictive value of the rule-out cutoff to exclude acute HF. Secondary endpoints included sensitivity, specificity, and positive (+) and negative (−) likelihood ratios (LRs) for acute HF.

The scientists reported that of 1,461 subjects, 277 (19%) were adjudicated as having acute HF. The median NT-proBNP concentration of patients with acute HF (2,844 pg/mL; interquartile range: 1,247 to 5,976 pg/mL) was substantially higher than those without acute HF (98 pg/mL; interquartile range: 35 to 369 pg/mL). The area under the receiver-operating characteristic curve for diagnosis of acute HF was 0.91. Sensitivity for age-stratified cutoffs of 450, 900, and 1,800 pg/mL was 85.7%, 79.3%, and 75.9%, respectively; specificity was 93.9%, 84.0%, and 75.0%, respectively. Positive predictive values were 53.6%, 58.4%, and 62.0%, respectively. The sensitivity and negative predictive value for the rule-out cutoff of 300 pg/mL were 93.9% and 98.0%, respectively; LR− was 0.09.

The authors concluded that in acutely dyspneic patients seen in the ED setting, age-stratified NT-proBNP cut-off points may aid in the diagnosis of acute HF. An NT-proBNP <300 pg/ml strongly excludes the presence of acute HF. James Januzzi Jr., MD, a Professor of Medicine and lead author of the study, said, “We found no specific population in which the test did not perform well, and what was most striking to me - as someone who has been working with NT-proBNP since the early 2000s - was how consistent these results were with those of prior studies. Given the changes in the types of patients with heart failure we see today, it's quite remarkable how reliable this test is.” The study was published on March 20, 2018, in the Journal of the American College of Cardiology.

Related Links:
Massachusetts General Hospital

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.